Gilead Science Day service once-time Fumaolinol proofaverve tablets approved by China's National Drug Administration

yesterday (November 19), Gilead Sciences (NASDAQ: GILD) announced that China's NationalMedicines(http://Regulatory Authority approved a one-time pvorted propofol tinoforave (Veridente ®, TAF, propofol at 25mg) that can be used to treat adults and adolescents (over 12 years of age, weighing at least 35kg) of chronic hepatitis B(HBV)theof theof the newof theof the Vrida ®
® Thedrug(http:// of the Neuforth avehorte, which has been shown to be similar to the antiviral efficacy of gileadvered ® (fumaricfort/TDF, 300 mg), but at a dose of only one-tenth that of the latterdata show that Verido ® have greater plasma stability than the ®, and can more effectively pass on tinofovweto to liver cells, so that the drug can be given in smaller doses, thereby reducing the amount of blood-borne noofforvirClinical trials have shown that The ® improves the safety parameters of the kidney and bone laboratory compared to the ® of the Wellredrelated studiesthe approval of the ® of Willid is based on data from two international phase III studies (108 and 110) involving 1,632 first-term and treated adult HBeAg-negative and HBeAg-positive HBV infections (including 334 patients treated in China)In a combination of two studies
analysis of (http:// , patients taking the Vrid ® improved in terms of bone and kidney laboratory parameters than those taking the Verede ® in addition, during the 96-week treatment period, none of the patients developed the drug resistance ® was approved by the U.S Food and Drug Administration and Japan's Ministry of Health, Labor and Welfare in 2016 and the European Commission in 2017